These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30864298)

  • 1. Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study.
    Tsuno N; Mori T; Ishikawa I; Bando N; Park H; Matsumoto Y; Mori I; Tanaka M; Hirano T; Nakamura Y
    Geriatr Gerontol Int; 2019 Jul; 19(7):571-576. PubMed ID: 30864298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study.
    Colombo D; Caltagirone C; Padovani A; Sorbi S; Spalletta G; Simoni L; Ori A; Zagni E
    J Womens Health (Larchmt); 2018 Nov; 27(11):1368-1377. PubMed ID: 30085899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
    Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
    Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
    Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
    PLoS One; 2017; 12(8):e0182123. PubMed ID: 28786987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
    Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
    Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease.
    Isaacson RS; Ferris S; Velting DM; Meng X
    Am J Alzheimers Dis Other Demen; 2016 May; 31(3):270-7. PubMed ID: 26371345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine Comparative Trial study).
    Yoon SJ; Choi SH; Na HR; Park KW; Kim EJ; Han HJ; Lee JH; Shim YS; Na DL
    Geriatr Gerontol Int; 2017 Mar; 17(3):494-499. PubMed ID: 27111084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
    Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
    CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
    Pregelj P
    Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease.
    Kuroda A; Setoguchi M; Uchino Y; Nagata K; Hokonohara D
    Geriatr Gerontol Int; 2018 Jun; 18(6):886-891. PubMed ID: 29441654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.
    Dhillon S
    Drugs Aging; 2011 Nov; 28(11):927-30. PubMed ID: 22054233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
    Dhillon S
    Drugs; 2011 Jun; 71(9):1209-31. PubMed ID: 21711064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease.
    Servello A; Ettorre E; Cacciafesta M
    Panminerva Med; 2017 Sep; 59(3):275-277. PubMed ID: 28665099
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
    Grossberg G; Cummings J; Frölich L; Bellelli G; Molinuevo JL; Krahnke T; Strohmaier C
    Am J Alzheimers Dis Other Demen; 2013 Sep; 28(6):583-91. PubMed ID: 23982674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.